TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04586036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 1
Description: The influence of ankle joint brace 1 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 1
Description: The influence of ankle joint brace 1 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 2
Description: The influence of ankle joint brace 2 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 2
Description: The influence of ankle joint brace 2 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 3
Description: The influence of ankle joint brace 3 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 3
Description: The influence of ankle joint brace 3 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 4
Description: The influence of ankle joint brace 4 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 4
Description: The influence of ankle joint brace 4 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 5
Description: The influence of ankle joint brace 5 on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ankle joint brace 5
Description: The influence of ankle joint brace 5 on gait biomechanics
Study: NCT00685893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local Champions
Description: We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Institution Feedback
Description: We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Institutional Forms
Description: We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
Study: NCT03244787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient navigation
Description: Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
Study: NCT02706067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
Study: NCT03746418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Guided Bilateral single shot Erector Spinae Plane Block
Description: Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Bilateral single shot Erector Spinae Plane Block
Description: Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
Study: NCT01573858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment 1
Description: Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment 1
Description: Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment 2
Description: Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
Study: NCT02294149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mammalian Omega 3 Fatty acids
Description: A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04867135

Intervention type: DRUG
Intervention: Amikacin Sulfate Injection
Description: The dose and frequency of amikacin was defined by each hospital.
Study: NCT04719169

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic MRI enema
Description: Dynamic MRI enema
Study: NCT04138706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
Study: NCT02082249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-SLV187
Description: Dose levels will be individually optimized
Study: NCT04292015

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optos ultra-widefield retinal imaging (Optos California)
Description: retinal imaging device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optos ultra-widefield retinal imaging (Optos California)
Description: retinal imaging device
Study: NCT01035476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data Card Report
Description: Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
Study: NCT02075034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
Study: NCT01625117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A variant of Narrative Exposure Therapy
Description: During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
Study: NCT02445287

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
Study: NCT02361814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of amnionic membrane allograft
Description: After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
Study: NCT05420116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cerdanya on Fitness
Description: The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
Study: NCT02407067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ChatterVox
Description: A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Listener FM system (Phonic Ear Corp.)
Description: A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System
Study: NCT01225055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 ug daily over 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 ug daily over 12 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibration
Description: 10 min/day for 12 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibration
Description: 10 min/day for 12 months
Study: NCT02994394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Study: NCT03952585

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT03952585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01573858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment 2
Description: Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Study: NCT03952585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01573858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Study: NCT04258748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaming and MI
Description: In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dental health education
Description: It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
Study: NCT01158859

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: Preoperative administration of pregabalin vs placebo 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Preoperative administration of pregabalin vs placebo 1 hour before surgery
Study: NCT06343623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myomucosal resection and direct closure
Description: myomucosal resection and direct closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superiorly based flap
Description: superiorly based pharyngeal flap
Study: NCT03477422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)
Description: CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
Study: NCT03498716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-dense Doxorubicin or dose-dense Epirubicin
Description: Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose-dense Doxorubicin or dose-dense Epirubicin
Description: Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses